Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
3-year Follow-up
100%
95% Confidence Interval
100%
Adverse Events
11%
B Cell Recovery
11%
CD19+
11%
Complete Response
33%
Complete Response Rate
11%
Cytokine Release Syndrome
11%
Durable Remission
11%
Duration of Response
11%
Effective Treatment
11%
Efficacy Data
11%
End of Treatment
11%
Extended Follow-up
11%
Fixation Duration
11%
Fixed-duration Therapy
11%
Follicular Lymphoma
100%
High Response Rate
11%
High-risk Disease
11%
Inotuzumab
100%
Kaplan-Meier
11%
Line of Therapy
11%
Malignant B Cells
11%
Median Overall Survival
11%
Median Progression-free Survival
11%
Median Time
11%
Objective Response Rate
11%
Overall Survival Rate
11%
Phase 1/2 Study
11%
Relapsed/refractory
100%
Relapsed/refractory Follicular Lymphoma
22%
Remission Rate
11%
Response Rate
11%
Safe Treatment
11%
Safety Data
11%
T Cell Bispecific Antibodies
11%
T Cells
11%
Medicine and Dentistry
Adverse Event
16%
B Cell
33%
Bispecific Antibody
16%
Cytokine Release Syndrome
16%
Diseases
16%
Effective Treatment
16%
Follicular Lymphoma
100%
Median Follow Up
16%
Mosunetuzumab
100%
Outpatient
16%
Overall Survival
33%
Progression Free Survival
16%
Spontaneous Remission
16%
Survival Rate
16%
T Cell
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
16%
Bispecific Antibody
16%
Cytokine Release Syndrome
16%
Diseases
16%
Follicular Lymphoma
100%
Mosunetuzumab
100%
Overall Survival
33%
Progression Free Survival
16%
Remission
33%
Survival Rate
16%
Immunology and Microbiology
B Cell
33%
Bispecific Antibody
16%
CD19
16%
Cytokine Release Syndrome
16%
Mosunetuzumab
100%
Overall Survival
33%
Progression Free Survival
16%
Survival Rate
16%
T Cell
33%